/HUMDF
HUMDF Stock - Hua Medicine (Shanghai) Ltd.
Healthcare|Drug Manufacturers - Specialty & GenericOTC
$0.41+0.00%
+$0.00 (+0.00%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.45
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HUMDF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.41 – $0.41
TARGET (TP)$0.47
STOP LOSS$0.38
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.22
52W High$0.41
52W Low$0.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $255.89M | $76.61M | $17.60M | N/A | $8.66M |
| Gross Profit | $124.72M | $37.37M | $7.69M | N/A | $8.66M |
| Gross Margin | 48.7% | 48.8% | 43.7% | N/A | 100.0% |
| Operating Income | $-352,644,000 | $-289,092,000 | $-267,117,999 | $-320,517,000 | $-352,382,000 |
| Net Income | $-250,144,000 | $-211,234,000 | $-203,766,000 | $-330,951,000 | $-396,429,000 |
| Net Margin | -97.8% | -275.7% | -1157.8% | N/A | -4575.6% |
| EPS | $-0.25 | $-0.22 | $-0.21 | $-0.34 | $-0.41 |
Company Overview
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HUMDFBeat Rate
75%
Last 8 quarters
Avg Surprise
-15.8%
EPS vs Estimate
Beats / Misses
6/2
Last 12 quarters
Latest EPS
$-0.02
Q4 2024
EPS Surprise History
Q1 22
+3.1%
$-0.03vs$-0.03
Q2 22
+48.1%
$-0.02vs$-0.03
Q4 22
No data
Q1 23
-147.3%
$-0.01vs$0.03
Q2 23
-126.6%
$-0.01vs$0.05
Q4 23
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q1 2025 | Mar 26, 2025 | — | — | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.02 | — | — |
Q1 2024 | Mar 28, 2024 | $0.07 | — | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | $0.05 | $-0.01 | -126.6% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $0.03 | $-0.01 | -147.3% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | $-0.03 | $-0.02 | +48.1% | ✓ BEAT |
Q1 2022 | Mar 16, 2022 | $-0.03 | $-0.03 | +3.1% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 30, 2021 | $-0.04 | $-0.03 | +27.5% | ✓ BEAT |
Q1 2021 | Mar 19, 2021 | $-0.04 | $-0.04 | +16.5% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $-0.04 | — | — |
Q2 2020 | Jun 30, 2020 | $-0.04 | $-0.03 | +32.2% | ✓ BEAT |
Q1 2020 | Mar 16, 2020 | $-0.04 | $-0.03 | +20.4% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | — | $-0.03 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.04 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.45 | — | — |
Latest News
Loading news...
Frequently Asked Questions about HUMDF
What is HUMDF's current stock price?
Hua Medicine (Shanghai) Ltd. (HUMDF) is currently trading at $0.41 per share. The stock has moved +0.00% today.
What is the analyst price target for HUMDF?
No analyst price targets are currently available for this stock.
What sector is Hua Medicine (Shanghai) Ltd. in?
Hua Medicine (Shanghai) Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.
What is HUMDF's market cap?
Hua Medicine (Shanghai) Ltd. has a market capitalization of $0.40 billion, making it a small-cap company.
Does HUMDF pay dividends?
No, Hua Medicine (Shanghai) Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGYTF
Allergy Therapeutics plc
$0.11
Mkt Cap: $0.5B
BOIRF
Boiron S.A.
$30.00
Mkt Cap: $0.5B
CLVLY
Clinuvel Pharmaceuticals Limited
$8.38
Mkt Cap: $0.4B
CRLBF
Cresco Labs Inc.
$1.30
Mkt Cap: $0.4B
HNSBF
Hansa Biopharma AB (publ)
$2.91
Mkt Cap: $0.2B
IOBCF
Ion Beam Applications S.A.
$13.25
Mkt Cap: $0.4B
KHTRF
Knight Therapeutics Inc.
$4.41
Mkt Cap: $0.4B
NIKA
Nika Pharmaceuticals Inc.
$0.28
Mkt Cap: $0.3B
PTCHF
PureTech Health plc
$1.55
Mkt Cap: $0.4B
VRNOF
Verano Holdings Corp.
$1.74
Mkt Cap: $0.6B
Explore stocks similar to HUMDF for comparison